
ATRICURE INC
ATRCNASDAQTrading Snapshot
- Day Range
- $42.77 โ $43.73
- 52-Week Range
- $25.36 โ $43.18
- Volume
- $5.94B
- Avg Volume
- $6.42B
- Shares Outstanding
- 50.9M
- Next Earnings
- Oct 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $535M
- Last Q Revenue
- $154M
- P/E Ratio
- 202.4
- P/S Ratio
- 3.8x
- EPS (TTM)
- $0.22
- Dividend Yield
- 0.00%
Why Investors Own ATRC
- โHigh-growth profile โ revenue up -5.1% YoY with expanding US Equity exposure.
- โHealthy economics โ 49% gross margin and 29% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ATRICURE INC
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

Director At AtriCure Sells $134K Of Stock
It was reported on August 7, that Maggie Yuen, Director at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and

Project Horizon and Outlook Upgrade Might Change The Case For Investing In Inspire Medical Systems (INSP)
Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite a year-on-year decline. Alongside these governance changes, Inspire raised its full-year outlook and launched Project Horizon, aimed at unlocking US$30 million in annualized investment...

Insider Selling: Vinayak Doraiswamy Unloads $233K Of AtriCure Stock
It was reported on July 30, that Vinayak Doraiswamy, Chief Scientific Officer at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with

Board Member At AtriCure Exercises Options Worth $491K
A significant insider transaction involving the exercise of company stock options was reported on July 30, by Sven Wehrwein, Board Member at AtriCure (NASDAQ:ATRC), as per the latest SEC filing. What Happened: A Form 4